A clinical trial is research designed to determine the most effective and safest ways to treat a disease and improve survival rates. Clinical trials often provide children with rare or hard-to-treat conditions like brain tumors with access to innovative treatments that may help where traditional options fail.
C.S. Mott Children’s Hospital is home to the largest cutting-edge pediatric cancer research effort in the state of Michigan. Our pediatric oncology program currently offers dozens of clinical trials for children’s cancers, many of which were developed here at U-M.
We encourage patients and families to contact our pediatric oncology clinic for more information and a current list of trials currently available for U-M patients.
U-M Investigator Initiated Trials for Brain Tumor Patients
Pediatric MI-ONCOSEQ: Personalized Medicine based on Molecular Profiling of Pediatric and Young Adult Patients with Cancer
Principal Investigators: Rajen Mody, MD, MS, and Arul Chinnaiyan, MD, PhD
Currently Enrolling
A Phase II Study of Dasatinib in Combination with Everolimus for Children with Gliomas Harboring PDGFR/FGFR Alterations
Principal Investigator: Carl Koschmann, MD
Currently Enrolling
A Phase II Study of Panobinostat in Combination with Everolimus for Children with Gliomas Harboring H3.3/H3.1 K27M
Principal Investigator: Carl Koschmann, MD
Projected Opening: Summer 2018
Pediatric Brain Tumor Cerebrospinal Fluid (CSF) Fluid Registry
Principal Investigator: Carl Koschmann, MD
Currently Enrolling
Non-U-M Initiated Clinical Trials Available at U-M for Brain Tumor Patients
A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
U-M Site Principal Investigator: Patricia Robertson, MD
Host Site: Lurie Children’s Hospital
Currently Enrolling
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
U-M Site Principal Investigator: Carl Koschmann, MD
Host Site: Nationwide Children’s Hospital
Currently Enrolling
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
U-M Site Principal Investigator: Carl Koschmann, MD
Host Site: Colorado Children’s Hospital
Projected U-M Site Opening: Summer 2018
DIPG Registry and Repository
U-M Site Principal Investigator: Carl Koschmann, MD
Host Site: Cincinnati Children’s Hospital
Currently Enrolling
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Principal Investigator: Carl Koschmann, MD
Host Site: Oncoceutics
Currently Enrolling
COG Phase I Trials for Brain Tumor Patients
ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
U-M Site Principal Investigator: Rajen Mody, MD, MS
Active, Not Currently Enrolling
WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling
WEE1 Inhibitor MK-1775 and Irinotecan in Treating Younger Patients With Relapsed or Refractory Solid Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling Medulloblastoma or CNS PNET
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
U-M Site Principal Investigator: Rajen Mody, MD, MS
Active, Not Currently Enrolling
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Winter or Spring 2017
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling
Pevonedistat, Temozolomide, and Irinotecan in Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Winter 2017 or Spring 2018
COG Phase II-III Trials for Brain Tumor Patients
ACNS0332 - Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
U-M Site Principal Investigator: Patricia Robertson, MD
Temporarily Closed to Accrual
ACNS0831 - Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
U-M Site Principal Investigator: Patricia Robertson, MD
Currently Enrolling
ADVL1621 - A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
U-M Site Principal Investigator: Rajen Mody, MD, MS
Closed to Accrual
ALTE07C1 - Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
U-M Site Principal Investigator: Patricia Robertson, MD
Currently Enrolling
ADVL1622 - Phase II Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling
ACNS1422 - A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
U-M Site Principal Investigator: Rajen Mody, MD, MS
Currently Enrolling
